Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
Want to see MLYS full AI Analyst Report?
MLYS Stock Chart & Stats
$30.58
-$0.99(-7.63%)
At close: 4:00 PM EST
$30.58
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$12.59 - $47.65
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.40M
Market Cap
$2.44B
Enterprise Value$1.85B
Total Cash (Recent Filing)$112.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding82,498,100
10 Day Avg. Volume1,337,411
30 Day Avg. Volume1,395,830
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.80
Price to Sales (P/S)0.00
P/FCF Ratio-17.24
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.88K
Enterprise Value/Ebitda-11.03
Forecast
1Y Price Target
$51.17Price Target Upside67.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In HypertensionConsistent and meaningful reductions in blood pressure on top of standard therapies, together with an acceptable safety and tolerability profile in trials, support clinical benefit for patients with uncontrolled hypertension.
Mechanism And Unmet NeedThe aldosterone synthase inhibitor mechanism targets an identifiable aldosterone-linked subset of hard-to-control patients, offering a differentiated therapeutic option that could validate the drug class and expand treatment choices.
Regulatory ProgressFDA acceptance of the new drug application and assignment of a formal review date indicate a clear regulatory pathway that could lead to approval and enable a planned commercial launch.
Bears Say
Commercial Strategy UncertaintyAbsence of a disclosed, detailed commercial launch plan creates questions about how the drug will be positioned, promoted, and supported for uptake among physicians and payers.
Safety And Competitive DifferentiationRemaining uncertainties about comparative efficacy, hyperkalemia risk, differences in drug half-life, and potential labeling or access restrictions could complicate prescribing choices if multiple similar therapies reach the market.
Sleep Apnea Trial SetbackA midstage study in obstructive sleep apnea failed to meet its primary endpoint for reducing apnea severity, creating uncertainty about benefit and development prospects for that indication.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $12.59 and its highest was $47.65 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $2.44B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 100 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.002.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 82,498,100 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went down -2.556%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mineralys Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.17 (67.32% Upside)
$51.17 (67.32% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 697.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
129.06%
12-Months-Change
Fundamentals
Return on Equity
-27.92%
Trailing 12-Months
Asset Growth
221.42%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive progress on the clinical and regulatory front with NDA acceptance and a clear PDUFA date, supported by a broad dataset and active prelaunch preparations. Financially, the company retains a substantial cash balance with runway into 2028 and showed reduced R&D spend following completion of pivotal work. Offsetting risks include a sizeable increase in G&A/prelaunch costs, continued quarterly net losses, competitive timing and pricing pressure from AstraZeneca’s expected earlier launch, and unresolved partnering and labeling/pricing uncertainties. On balance, the company appears well positioned operationally and clinically, but near-term commercial and financial execution risks remain.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$51.17
▲(67.32% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Apellis Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Centessa Pharmaceuticals
―
Ownership Overview
27.05% Insiders
17.84% Mutual Funds
3.55% Other Institutional Investors
41.75% Public Companies and
Individual Investors